ArticleNPJ science of food2025
Revealing the mechanism of Ganoderma lucidum insoluble dietary fiber alleviating NAFLD through transcriptomics and metabolomics.
Article in NPJ science of food, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimized Extraction of Soluble Dietary Fiber fromFoods (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The study established a mouse model of NAFLD induced by a 12-week high-fat diet (HFD). Utilizing hepatic transcriptomics, 16S rDNA sequencing, and metabolomics, the study examined the mechanisms by which GIDF exerts hepatic protection and modulates lipid metabolism in NAFLD through the gut-liver axis.The results demonstrated that GIDF supplementation significantly alleviated NAFLD characteristics in mice, including reducing biomarkers associated with hepatic lipid deposition and injury(Serum cholesterol, Serum triglycerides, lipopolysaccharide (LPS), TNF-α, etc.), modulating lipid disorders, and improving oxidative stress. GIDF likely regulated lipid metabolism through pathways such as Cytochrome P450, Retinol metabolism, and PPAR signaling, while increasing the expression of ileal tight junction proteins (ZO-1 and Occludin), thereby repairing the intestinal barrier.GIDF altered gut microbiota composition, promoting the growth of Lactobacillus and Akkermansia.Furthermore, GIDF upregulated levels of L-cysteine, S-adenosylmethionine (SAMe), and 5'-methylthioadenosine (MTA), while downregulating 13(S)-HODE. These findings validate that GIDF alleviates NAFLD and may serve as a promising nutritional supplement.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.